Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína3. fázis

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

A legfontosabb adatok

Ki végzi
Takeda
Hol
Beijing, Changsha, Changzhou, Foshan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Huizhou, Kunming, Lanzhou, Nanchang, Nanjing, Nanyang, Ningbo, Qingyuan, Quzhou, Shanghai, Shenzhen, Shenyang, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wenzhou, Wuhan, Wuhu, Xuzhou, Yancheng, Yantai, Yinchuan, Zhenjiang és Zhuhai (Kína)Mind a 43 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
408 fő, tervezett
Kezdés
2023. jún. 16.
Várható befejezés
2031. máj. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Vedolizumab IV
  • Placebo
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan kínai felnőtteket keres, akiknek közepesen súlyos vagy súlyos, aktív Crohn-betegségük van, és a korábbi kezelésre nem reagáltak jól, a kezelés hatása elmúlt, vagy nem tolerálták.

Életkor
18–80 év
Nem
Minden nem részt vehet
A betegség stádiuma
Közepesen súlyos vagy súlyos, aktív Crohn-betegség, amelyet legalább 3 hónappal a szűrés előtt diagnosztizáltak. A betegségnek legalább a csípőbelet és/vagy a vastagbelet érintenie kell.
Korábbi kezelés
Az alábbiak közül legalább 1-re nem volt megfelelő a válasz, a hatás elmúlt, vagy nem tolerálta: kortikoszteroidok, immunmodulátorok vagy TNF-α-gátlók. Korábban nem kaphatott vedolizumabot vagy más anti-integrin gyógyszert.
Biomarker vagy leletérték
A betegség aktivitását mérő pontszámok: PRO2 pontszám 14 és 34 pont között, és SES-CD pontszám ≥6 (vagy ≥4 izolált ileitis esetén) a szűrés során végzett ileokolonoszkópián.

A részvétel fő kizáró okai

  • Hasi tályog, sztóma vagy a bél fix szűkülete
  • Krónikus hepatitis B vagy C, aktív vagy látens tuberkulózis, vagy aktív fertőzés
  • Immunhiány, például HIV-fertőzés vagy szervátültetés
  • Bármilyen korábbi daganatos betegség, néhány kivétellel (egyes bőrrákok, méhnyak in situ carcinoma)
  • Korábbi vedolizumab- vagy más anti-integrin-kezelés

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • The participant has a diagnosis of CD established at least 3 months before screening by clinical and endoscopic evidence corroborated by a histopathology report. Cases of CD established at least 6 months before randomization for which a histopathology report is not available will be considered based on the weight of evidence supporting the diagnosis and excluding other potential diagnoses, and must be discussed with the sponsor on a case-by-case basis before randomization
  • The participant has moderately to severely active CD as determined by a 2-component patient-reported outcome (PRO2) score of 14 to 34 points and a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≥6 (or ≥4 in cases of isolated ileitis) on screening ileocolonoscopy
  • The participant has CD involvement of the ileum and/or colon, at a minimum
  • A participant with extensive colitis or pancolitis of >8 years duration or limited colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months before initial screening (may be performed during screening if not performed in previous 12 months)
  • A participant with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during screening)
  • The participant has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:; Corticosteroids; Immunomodulators; TNF-α antagonists

Ki nem vehet részt

  • The participant has had extensive colonic resection, subtotal or total colectomy
  • The participant has received tube feeding, defined formula diets, or parenteral alimentation within 21 days before administration of the first dose of study drug
  • Within 30 days before randomization, the participant has received any of the following for the treatment of underlying disease:; Nonbiologic therapies (eg, cyclosporine, thalidomide) other than those specifically listed in the Permitted Medications and Treatments section; An approved or investigational nonbiologic therapy in an investigational protocol
  • The participant has received traditional Chinese medication (TCMs) within 30 days before randomization
  • The participant has had previous exposure to approved or investigational anti-integrins including, but not limited to natalizumab, efalizumab, etrolizumab, or abrilumab (AMG-181), or mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) antagonists, or rituximab
  • The participant has had previous exposure to vedolizumab
  • The participant has used topical (rectal) treatment with 5-aminosalicylic acid (5-ASA), corticosteroid enemas/suppositories or traditional Chinese medications for CD treatment within 2 weeks of the administration of the first dose of study drug
  • The participant requires currently or is anticipated to require surgical intervention for CD during the study
  • The participant has evidence of treatment for Clostridioides difficile (C difficile) infection or other intestinal pathogen within, 28 days before first dose of study drug
  • The participants has received any live vaccinations within 30 days before screening
  • The participant has a clinically significant active infection (eg, pneumonia, pyelonephritis, or coronavirus disease 2019 [COVID-19]) within 30 days before screening or during screening, or has an ongoing chronic infection or any ongoing COVID-19-related symptom(s), if previously diagnosed as having COVID-19; General Exclusion Criteria
  • The participant has had any surgical procedure requiring general anesthesia within 30 days before enrollment or is planning to undergo major surgery during the study period
  • The participant has a history of >3 small bowel resections or diagnosis of short bowel syndrome
  • The participant has a history or evidence of colonic mucosal dysplasia including low or high-grade dysplasia, as well as indeterminate for dysplasia; Infectious Disease Exclusion Criteria
  • The participant has evidence of active infection during the screening period
  • The participant has chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection
  • The participant has active or latent tuberculosis (TB)
  • The participant has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)
  • The participant has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease
  • The participant has any history of malignancy, except for the following: (a) adequately-treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and has not recurred for at least 1 year before randomization; and (c) history of cervical carcinoma in situ that has been adequately treated and has not recurred for at least 3 years before randomization. Participants with remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis before randomization
  • Gastrointestinal (GI) Exclusion Criteria:
  • The participant has evidence of abdominal abscess at the initial screening visit
  • The participant has had ileostomy, colostomy, known fixed symptomatic stenosis of the intestine, or evidence of fixed stenosis, or small bowel stenosis with prestenotic dilation
  • The participant has a history or evidence of adenomatous colonic polyps that have not been removed

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Helyszínek itt: Kína

  • Peking University Third HospitalBeijing, KínaContact: Shigang Ding (principal investigator)Résztvevőt keres
  • Peking University First Hospital - Changqiao CampusBeijing, KínaNo longer taking part
  • The Second Xiangya Hospital of Central South UniversityChangsha, KínaContact: Xuehong Wang (principal investigator)Résztvevőt keres
  • Changzhou No.2 People's Hospital - Yanling CampusChangzhou, KínaContact: Wenjia Liu (principal investigator)Résztvevőt keres
  • The First People's Hospital of FoshanFoshan, KínaContact: Zhaotao Li (principal investigator)Résztvevőt keres
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, KínaContact: Chengdang Wang (principal investigator)Résztvevőt keres
  • Guangzhou First People's HospitalGuangzhou, KínaContact: Yongjian Zhou (principal investigator)Résztvevőt keres
  • The First Affiliated Hospital, Sun Yat-sen University - MainGuangzhou, KínaContact: Baili Chen (principal investigator)Résztvevőt keres
  • The second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, KínaContact: Hui Yang (principal investigator)Résztvevőt keres
  • The Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, KínaContact: Xiang Gao (principal investigator)Résztvevőt keres
  • The Third Affiliated Hospital,Sun Yat-Sen UniversityGuangzhou, KínaNo longer taking part
  • The 2nd Affliated Hospital of Harbin Medical UniversityHaerbin, KínaContact: Bo Qu (principal investigator)Résztvevőt keres
  • The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDSHangzhou, KínaContact: Chunxiao Chen (principal investigator)Résztvevőt keres
  • The Second Hospital of Anhui Medical UniversityHefei, KínaContact: Xiangpeng Hu (principal investigator)Résztvevőt keres
  • Huizhou Central People's HospitalHuizhou, KínaContact: Huixin Chen (principal investigator)Résztvevőt keres
  • The First People's Hospital of Yunnan ProvinceKunming, KínaContact: Zhengji Song (principal investigator)Résztvevőt keres
  • Lanzhou University Second HospitalLanzhou, KínaContact: Dekui Zhang (principal investigator)Résztvevőt keres
  • The Second Affiliated Hospital of Nanchang University - Donghu CampusNanchang, KínaContact: Zhili Wen (principal investigator)Résztvevőt keres
  • Zhongda Hospital Affiliated to Southeast UniversityNanjing, KínaContact: Hong Chen (principal investigator)Résztvevőt keres
  • Nanyang First People's HospitalNanyang, KínaContact: Chunxian Gao (principal investigator)Résztvevőt keres
  • The First Affiliated Hospital of Ningbo University - Fangqiao CampusNingbo, KínaContact: Qi Jiang (principal investigator)Résztvevőt keres
  • Qingyuan People's HospitalQingyuan, KínaNo longer taking part
  • People's Hospital of QuzhouQuzhou, KínaNo longer taking part
  • Shanghai Changhai HospitalShanghai, KínaContact: Yiqi Du (principal investigator)Résztvevőt keres
  • Shanghai East Hospital - MainShanghai, KínaContact: Lan Zhong (principal investigator)Résztvevőt keres
  • Zhongshan Hospital,Fudan UniversityShanghai, KínaNo longer taking part
  • The University of Hong Kong-Shenzhen HospitalShenzhen, KínaContact: Wai-Kay Seto (principal investigator)Résztvevőt keres
  • Shengjing Hospital of China Medical University (Nanhu Campus)Shenyang, KínaContact: Changqing Zheng (principal investigator)Résztvevőt keres
  • The Second Hospital of Hebei Medical University - MainShijiazhuang, KínaNo longer taking part
  • Changshu No.2 People's HospitalSuzhou, KínaContact: Lanxiang Zhu (principal investigator)Résztvevőt keres
  • Taizhou Hospital of Zhejiang Province - MainTaizhou, KínaContact: Xinli Mao (principal investigator)Résztvevőt keres
  • The First People's Hospital of WenlingTaizhou, KínaContact: Haifan Yan (principal investigator)Résztvevőt keres
  • Tianjin Medical University General HospitalTianjin, KínaContact: Bangmao Wang (principal investigator)Résztvevőt keres
  • The 1st Affiliated Hospital of Wenzhou Medical University - Nanbaixiang CampusWenzhou, KínaNo longer taking part
  • Renmin Hospital of Wuhan University - Main CampusWuhan, KínaContact: Ping An (principal investigator)Résztvevőt keres
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Xiaohua Hou (principal investigator)Résztvevőt keres
  • Yijishan Hospital of Wannan Medical CollegeWuhu, KínaContact: Chiyi He (principal investigator)Résztvevőt keres
  • Xuzhou Central HospitalXuzhou, KínaNo longer taking part
  • Yancheng NO.1 People's HospitalYancheng, KínaContact: Hongmei Yang (principal investigator)Résztvevőt keres
  • Yantai Yuhuangding HospitalYantai, KínaNo longer taking part
  • People's Hospital of Ningxia Hui Aotonomous RegionYinchuan, KínaNo longer taking part
  • Affiliated Hospital of Jiangsu UniversityZhenjiang, KínaContact: Min Xu (principal investigator)Résztvevőt keres
  • The Fifth Affiliated Hospital Sun Yat-sen UniversityZhuhai, KínaContact: Xiaofeng Li (principal investigator)Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China. Participants will receive an injection of Vedolizumab 300 mg at scheduled weeks 0, 2, and 6, and starting at week 14, every 8 weeks over 58 weeks or starting at week 18, every 4 weeks over 54 weeks. There will be up to 20 study visits over 58 weeks to complete assessments.

A vizsgálat 3 csoportja

  • Induction Period: Vedolizumab 300 mgA vizsgált kezelés

    Participants will receive vedolizumab 300 mg IV infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.

    Kezelés: Vedolizumab IV

  • Induction Period: PlaceboPlacebo, összehasonlításként

    Participants will receive vedolizumab placebo-matching IV, infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.

    Kezelés: Placebo

  • Open-label Extension (OLE) Period: Vedolizumab 300 mgA vizsgált kezelés

    All participants completing the Week 14 visit, irrespective of their response status, will continue in the OLE without unblinding of their baseline treatment group and will receive vedolizumab 300 mg, IV infusion, Q8W, on Days 99, 155, 211, 267, 323, and 379 (Weeks 14, 22, 30, 38, 46 and 54). Starting from Day 127 (Week 18) until the end of OLE Period up to approximately 58 weeks, participants who are nonresponders or who have disease worsening are eligible to receive 300 mg vedolizumab Q4W.

    Kezelés: Vedolizumab IV

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-Controlled Induction Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Subjects in China With Moderately to Severely Active Crohn's Disease
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Illeszkedési kérdések
Forrás: NCT05837897: ki vehet részt
A regiszteradat frissítve
2026. november 2.